CG Oncology announces that data from the Phase 3 BOND-003 study evaluating the
efficacy and safety of cretostimogene monotherapy in patients with high-risk Non-Muscle
Invasive Bladder Cancer unresponsive to Bacillus Calmette Guerin, showed that 75.2% of
patients achieved a complete response at any time, as of the cutoff date of April 1, 2024
IPO Jan 25, 24: CG Oncology (CGON) priced upsized 20.0 mln share IPO $19.00 per share, above the $16-18 expected range
The IPO was upsized from 17.0 mln shares, which was upsized from the original 11.8 mlnshares.
Ticker: CGON
- Founded: 2010
- Headquarters: Irvine, California
- Website: cgoncology.com
- Employees: 61
No comments:
Post a Comment